- Active not recruitingPHASE3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
This study compares two treatments, XL092 (plus atezolizumab) and regorafenib, for advanced bowel cancer that has spread. It's for people whose cancer hasn't responded well to previous common treatments. We want to see which treatment works better to control the cancer.
For: Colorectal CancerUnited States · Australia · Belgium - RecruitingPHASE2, PHASE3
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
This study is testing different treatments for a type of brain cancer called glioblastoma. It's for people who have been recently diagnosed or whose cancer has come back. The aim is to find better ways to treat this cancer.
For: GlioblastomaUnited States · Australia · Canada - Active not recruitingPHASE3
Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients
This study is testing a new combination of two drugs, Regorafenib and Irinotecan, for people with advanced bowel cancer. It's comparing this new combination to Regorafenib on its own, to see if the combination works better when standard treatments are no longer effective.
For: Metastatic Colorectal Cancer (mCRC)France - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - AuthorisedTherapeutic exploratory (Phase II)
Monocentric Pilot Trial evaluating the safety and efficacy of Regorafenib in Arterio-Venous Malformations that are refractory to standard care
This study is testing a medicine called regorafenib for a rare condition called Arterio-Venous Malformations (AVMs). It's for people whose AVMs haven't improved with usual treatments. We want to see if the medicine can make people feel better, reduce their pain, and shrink their AVMs over 12 months.
For: Arterio-Venous MalformationsBelgium